Short-term surveillance of cytokines and C-reactive protein cannot predict efficacy of fecal microbiota transplantation for ulcerative colitis

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Zhang, Ting ^a   Cui, Bota ^a   Li, Pan ^a   He, Zhi ^a   Long, Chuyan ^a   Wei, Lu ^a   Peng, Zhaoyuan ^a   Ji, Guozhong ^a   Zhang, Faming ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; AUTACOID; BIOLOGICAL MARKER;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMAN; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECTUM HEMORRHAGE; ULCERATIVE COLITIS; BLOOD; CASE CONTROL STUDY; COLITIS, ULCERATIVE; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CYTOKINES; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84977138813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158227     Document Type: Article

References (44)

1. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc 2014; 89: 1553-63. doi: 10.1016/j.mayocp.2014.07.002 PMID: 25199861.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-25. doi: 10.1056/NEJMra1102942 PMID: 22047562.
3. Babickova J, Gardlik R. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease. World J Gastroenterol 2015; 21: 11321-30. doi: 10.3748/wjg.v21.i40.11321 PMID: 26525290; PubMed Central PMCID: PMCPmc4616208.
4. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? Am J Gastroenterol 2012; 107: 1755; author reply p.1755-6. doi: 10.1038/ajg.2012.251 PMID: 23160295.
5. Sha S, Liang J, Chen M, Xu B, Liang C, Wei N, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014; 39: 1003-32. doi: 10.1111/apt.12699 PMID: 24641570.
6. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology 2015; 149: 102-109.e6. doi: 10.1053/j.gastro.2015.04.001 PMID: 25857665.
7. Cui B, Li P, Xu L, Zhao Y, Wang H, Peng Z, et al. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. Journal Transl Med 2015; 13: 298. doi: 10.1186/s12967-015-0646-2 PMID: 26363929; PubMed Central PMCID: PMCPmc4567790.
8. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989; 1: 164. PMID: 2563083.
9. Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989; 150: 604. PMID: 2783214.
10. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013; 56: 597-601. doi: 10.1097/MPG.0b013e318292fa0d PMID: 23542823.
11. Gordon H, Harbord M. A patient with severe Crohn's colitis responds to Faecal Microbiota Transplantation. J Crohns Colitis 2014; 8: 256-7. doi: 10.1016/j.crohns.2013.10.007 PMID: 24239403.
12. Kao D, Hotte N, Gillevet P, Madsen K. Fecal microbiota transplantation inducing remission in Crohn's colitis and the associated changes in fecal microbial profile. J Clin Gastroenterol 2014; 48: 625-8. doi: 10.1097/mcg.0000000000000131 PMID: 24667590.
13. Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, et al. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology 2015; 149: 110-118.e4. doi: 10.1053/j.gastro.2015.03.045 PMID: 25836986.
14. Cui B, Feng Q, Wang H, Wang M, Peng Z, Li P, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 2015; 30: 51-8. doi: 10.1111/jgh.12727 PMID: 25168749.
15. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013; 108: 1620-30. doi: 10.1038/ajg.2013.257 PMID: 24060759.
16. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549. doi: 10.1146/annurev.immunol.20.100301.064816 PMID: 11861611.
17. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329-42. doi: 10.1038/nri3661 PMID: 24751956.
18. Francescone R, Hou V, Grivennikov SI. Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis 2015; 21: 409-18. doi: 10.1097/mib.0000000000000236 PMID: 25563695; PubMed Central PMCID: PMCPmc4481731.
19. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20: 6-21. doi: 10.3748/wjg.v20.i1.6 PMID: 24415853; PubMed Central PMCID: PMCPmc3886033.
20. Jiang W, Su J, Zhang X, Cheng X, Zhou J, Shi R, et al. Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm Res 2014; 63: 943-50. doi: 10.1007/s00011-014-0768-7 PMID: 25129403.
21. Coccia M, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, et al. IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells. J Exp Med 2012; 209: 1595-609. doi: 10.1084/jem.20111453 PMID: 22891275; PubMed Central PMCID: PMCPmc3428945
22. Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2- and interferongamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 1993; 78: 127-31. PMID: 8436398; PubMed Central PMCID: PMCPmc1421783.
23. Kai Y, Takahashi I, Ishikawa H, Hiroi T, Mizushima T, Matsuda C, et al. Colitis in mice lacking the common cytokine receptor gamma chain is mediated by IL-6-producing CD4+ T cells. Gastroenterology 2005; 128: 922-34. PMID: 15825075.
24. Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages. Gastroenterology 2011; 141: 2026-38. doi: 10.1053/j.gastro.2011.08.032 PMID: 21875498.
25. Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology 2009; 137: 1736-45. doi: 10.1053/j.gastro.2009.07.049 PMID: 19632232.
26. Geremia A, Arancibia-Carcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011; 208: 1127-33. doi: 10.1084/jem.20101712 PMID: 21576383; PubMed Central PMCID: PMCPmc3173242.
27. Caballero S, Pamer EG. Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu Rev Immunol 2015; 33: 227-56. doi: 10.1146/annurev-immunol-032713-120238 PMID: 25581310; PubMed Central PMCID: PMCPmc4540477.
28. Backhed F, Fraser CM, Ringel Y, Sanders ME, Sartor RB, Sherman PM, et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe 2012; 12: 611-22. doi: 10.1016/j.chom.2012.10.012 PMID: 23159051.
29. Schuijt TJ, van der Poll T, de Vos WM, Wiersinga WJ. The intestinal microbiota and host immune interactions in the critically ill. Trends Microbiol 2013; 21: 221-9. doi: 10.1016/j.tim.2013.02.001 PMID: 23454077.
30. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-86. doi: 10.1053/j.gastro.2006.12.038 PMID: 17258735.
31. Kump PK, Grochenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013; 19: 2155-65. doi: 10.1097/MIB.0b013e31829ea325 PMID: 23899544.
32. Cui B, Xu F, Zhang F. Methodology, Not Concept of Fecal Microbiota Transplantation, Affects Clinical Findings. Gastroenterology 2016; 150: 285-6. doi: 10.1053/j.gastro.2015.05.065 PMID: 26616573.
33. Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol 2015; 21: 11246-59. doi: 10.3748/wjg.v21.i40.11246 PMID: 26523100; PubMed Central PMCID: PMCPmc4616202.
34. Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology 2015; 149: 1275-1285.e2. doi: 10.1053/j.gastro.2015.07.003 PMID: 26166315.
35. Du Clos TW. Function of C-reactive protein. Ann Med 2000; 32: 274-8. PMID: 10852144.
36. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-8. doi: 10.1038/75068 PMID: 10802717.
37. Liu L, Guo Z, Lv Z, Sun Y, Cao W, Zhang R, et al. The beneficial effect of Rheum tanguticum polysaccharide on protecting against diarrhea, colonic inflammation and ulceration in rats with TNBS-induced colitis: the role of macrophage mannose receptor in inflammation and immune response. Int Immunopharmacol 2008; 8: 1481-92. doi: 10.1016/j.intimp.2008.04.013 PMID: 18790466.
38. Xanthoulea S, Pasparakis M, Kousteni S, Brakebusch C, Wallach D, Bauer J, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med 2004; 200: 367-76. doi: 10.1084/jem.20040435 PMID: 15289505; PubMed Central PMCID: PMCPmc2211976.
39. Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res 2005; 15: 24-7. doi: 10.1038/sj.cr.7290259 PMID: 15686622.
40. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119: 651-65. doi: 10.1182/blood-2011-04-325225 PMID: 22053109; PubMed Central PMCID: PMCPmc3265196.
41. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-59, quiz 660. doi: 10.1038/ajg.2011.73 PMID: 21407183.
42. Kleiner G, Zanin V, Monasta L, Crovella S, Caruso L, Milani D, et al. Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1beta, interleukin-2 and interleukin-17. Exp Ther Med 2015; 9: 2047-2052. doi: 10.3892/etm.2015.2370 PMID: 26136934; PubMed Central PMCID: PMCPmc4473502.
43. Holtmann MH, Douni E, Schutz M, Zeller G, Mudter J, Lehr HA, et al. Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo. Eur J Immunol 2002; 32: 3142-51. doi: 10.1002/1521-4141(200211)32:11〈3142::aid-immu3142〉3.0.co;2-4 PMID: 12555659.
44. Perrier C, de Hertogh G, Cremer J, Vermeire S, Rutgeerts P, Van Assche G, et al. Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis. Inflamm Bowel Dis 2013; 19: 246-53. doi: 10.1002/ibd.23023 PMID: 22649027.